WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406985
CAS#: 5812-07-7
Description: SU-4312, also known as DMBI, is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively). SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS.
Hodoodo Cat#: H406985
Name: SU-4312
CAS#: 5812-07-7
Chemical Formula: C17H16N2O
Exact Mass: 264.13
Molecular Weight: 264.330
Elemental Analysis: C, 77.25; H, 6.10; N, 10.60; O, 6.05
Synonym: SU-4312; SU 4312; SU4312. DMBI; NSC 86429; NSC-86429; NSC86429.
IUPAC/Chemical Name: 3-[[4-(dimethylamino)phenyl]methylene]-1,3-dihydro-2H-indol-2-one
InChi Key: UAKWLVYMKBWHMX-PTNGSMBKSA-N
InChi Code: UAKWLVYMKBWHMX-PTNGSMBKSA-N
SMILES Code: O=C1NC2=C(C=CC=C2)/C1=C/C3=CC=C(N(C)C)C=C3
Appearance: Yellow solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 264.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Li Y, Zhu H, Klausen C, Peng B, Leung PC. Vascular Endothelial Growth Factor-A
(VEGF-A) Mediates Activin A-Induced Human Trophoblast Endothelial-Like Tube
Formation. Endocrinology. 2015 Nov;156(11):4257-68. doi: 10.1210/en.2015-1228.
PubMed PMID: 26327470.
2: Cui W, Zhang Z, Li W, Hu S, Mak S, Zhang H, Han R, Yuan S, Li S, Sa F, Xu D,
Lin Z, Zuo Z, Rong J, Ma ED, Choi TC, Lee SM, Han Y. The anti-cancer agent SU4312
unexpectedly protects against MPP(+) -induced neurotoxicity via selective and
direct inhibition of neuronal NOS. Br J Pharmacol. 2013 Mar;168(5):1201-14. doi:
10.1111/bph.12004. PubMed PMID: 23062100; PubMed Central PMCID: PMC3594677.
3: Miki A, Miki K, Ueno S, Wersinger DM, Berlinicke C, Shaw GC, Usui S, Wang Y,
Zack DJ, Campochiaro PA. Prolonged blockade of VEGF receptors does not damage
retinal photoreceptors or ganglion cells. J Cell Physiol. 2010 Jul;224(1):262-72.
doi: 10.1002/jcp.22129. PubMed PMID: 20232317; PubMed Central PMCID: PMC4005719.
4: Schultheiss C, Blechert B, Gaertner FC, Drecoll E, Mueller J, Weber GF,
Drzezga A, Essler M. In vivo characterization of endothelial cell activation in a
transgenic mouse model of Alzheimer's disease. Angiogenesis. 2006;9(2):59-65.
PubMed PMID: 16821113.
